Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy…

Read the full article here

Source: New England Journal of Medicine
Categories: Hem/Onc News and Journals, Hem/Oncs, Latest Headlines
Tweets with this article
The Fellow on Call: The Heme/Onc Podcast
CAR-T therapy for large B-cell lymphoma continues to show promise compared to standard chemotherapy in the second-line setting based on the results of the ZUMA-7. We also hope this provides further justification to improve our CAR manufacturing times.

Related Articles